Study on the Mechanism of Yiqi Zengmian Fang and Huashibaidu Granules on New Coronary Pneumonia

Phase 1

Recruiting

• Conditions: ovel Coronavirus Pneumonia (COVID-19)

• Registration Number: ITMCTR2100005241
• Lead Sponsor: China Academy of Chinese Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1. Aged 18-59 years;
2. Consent to participate in this study.

Exclusion Criteria

1. Those who are allergic to any component of the vaccine, or who have experienced severe allergic reaction to the vaccine in the past, such as acute allergic reaction, urticaria, skin eczema, dyspnea, angioedema or abdominal pain;
2. Those who are allergic to the ingredients in Yiqi Zengmai Formula;
3. Subjects with fever, acute disease, severe chronic disease, or acute onset of chronic disease;
4. Pregnant subjects and lactating subjects, have a birth plan within 3 months of vaccination;
5. Those with a history or family history of convulsions, epilepsy, encephalopathy or mental illness; those with uncontrolled epilepsy and other progressive neurological diseases, those with a history of Guillain-Barre syndrome;
6. Has been diagnosed with congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia or other autoimmune diseases;
7. Known or suspected to suffer from severe respiratory disease, severe cardiovascular disease, liver and kidney disease, malignant tumor;
8. Those with a history of new coronavirus infection;
9. Taking drugs that may affect immune function, such as immunosuppressants or immune enhancers or glucocorticoids (>=10mg prednisone or other equivalent glucocorticoids) within or within one month before enrollment;
10. Those who are considered inappropriate by researchers or vaccination doctors to be vaccinated against the new crown inactivated vaccine.

Study & Design

• Study Type: Interventional study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Coronavirus disease RBD specific antibody levels;